Professional Marketing briefs: November 2012

Plavix ceded 90% of its market share to generics within two months
Plavix ceded 90% of its market share to generics within two months

Targacept announced on October 8 that its April layoff of 65 employees was not its last—the company will slim its workforce by another 38%, leaving it with 43 employees. The company plans on closing its lab operations by the end of the year. The company has had a number of recent setbacks, which include having to scrap an antidepressant it was developing with AstraZeneca.

Plavix and Avapro deals continue—even though the US patents for both drugs have lapsed. The latest deal is that Bristol-Myers Squibb is returning most of its ­Plavix rights to Sanofi, while holding onto its rights in the US and Puerto Rico. The deal gives BMS a royalty cut on both branded and unbranded Plavix sales worldwide (except for in the US) as well as on branded and unbranded Avapro sales worldwide.

Merck is planning to move its headquarters from Whitehouse Station to Summit, NJ. As a result of that change, the company will be shuttering the Whitehouse location. The proposed move will start in 2014 and is expected to be completed by mid-2015. The company expects the 2,000 Whitehouse employees will be distributed among the company's other locations.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.